RELEASE: Seegene Declares Sharing Syndromic PCR Technologies to Prevent Future Pandemics

SEOUL, South Korea, March 28, 2023/PRNewswire/ -- Seegene Inc.

RELEASE: Seegene Declares Sharing Syndromic PCR Technologies to Prevent Future Pandemics

SEOUL, South Korea, March 28, 2023/PRNewswire/ -- Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for molecular PCR diagnostics, has announced that it will start sharing its technologies syndromic PCR testing worldwide. Seegene aims to partner with nationally renowned companies in each country to locally develop and manufacture custom syndromic PCR tests through access to Seegene's proprietary technologies and expertise. This effort will enable partner companies to effectively address potential disease outbreaks and prevent future pandemics collaboratively.

The Seegene Collaborative Network aims to push the boundaries of what is possible with PCR while democratizing access to syndromic PCR testing. In general, only a few syndromic tests are developed each year. By embracing an open innovation model, Seegene invites leading companies from each country to join this network and collectively develop hundreds or even thousands of syndromic PCR assays annually to serve local and global markets. The creation of a sustainable global community will catalyze the development of novel and innovative applications for PCR technologies around the world.

Seegene highlighted its innovative automated testing system, 'One System', which will actualize the goal of decentralizing laboratory testing at an affordable price. "The biggest challenge in PCR molecular diagnostics is the number of different laboratory instruments needed to run assays from different manufacturers," said Dr. Jong-Yoon Chun, CEO of Seegene. "We believe that consolidating all PCR tests into a single system will revolutionize assay developer and user experiences in syndromic PCR testing."

On March 22, 2023, Seegene signed the first One System global partnership agreement with Israel's leading diagnostic company, Hy Laboratories Ltd (Hylabs). Seegene is committed to sharing its syndromic PCR technologies with Hylabs to address local needs and looks forward to engaging the Israeli scientific community in this global partnership. "This agreement will build on Hylab's five decades of leadership in microbiology and molecular diagnostics," said Doron Cohen, President of Hylabs. "This effort builds on the extensive 15-year collaboration of both companies as enablers of cutting-edge medical technology in public health."

The signing of this agreement marks the beginning of Seegene's proactive search for additional partners to join this global network that will leverage Seegene's syndromic PCR technologies, including One System, to improve the quality of life and well-being of people in everyone.

Seegene has 20 years of research experience dedicated to syndromic PCR technologies, which was highlighted during the COVID-19 pandemic when he delivered more than 340 million COVID-19 tests in more than 100 countries around the world. The central feature of Seegene's syndromic PCR technologies is the ability to simultaneously test 14 pathogens that cause similar symptoms in a single tube and provide quantitative information on the infectivity profile to correlate with disease severity.

Any country or company interested in accessing Seegene's syndromic PCR technologies and expertise, please contact

Logo -

View original content: